BackBrowsing by Author "Champagne, Devin"
Now showing items 1-2 of 2
-
miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease
Fernández Tussy, Pablo; Fernández Ramos, David; Lopitz Otsoa, Fernando; Simon, Jorge; Barbier Torres, Lucía; Gómez Santos, Beatriz; Nuñez García, Maitane; ; ; Gutiérrez de Juan, Virginia; ; Rodríguez Agudo, Rubén; Iruzubieta, Paula; Anguita Castillo, Juan de Dios; Castro, Rui E.; Champagne, Devin; Rincon, Mercedes; ; Arslanow, Anita; Krawczyk, Marcin; Lammert, Frank; Kirchmeyer, Melanie; Behrmann, Iris; Crespo, Javier; Lu, Shelly C.; Mato, José M.; Varela Rey, Marta; ; Delgado, Teresa C.; Martínez Chantar, María Luz
(Elsevier, 2019-08-16)
Objective: Non-alcoholic fatly liver disease (NAFLD) is a complex pathology in which several dysfunctions, including alterations in metabolic pathways, mitochondrial functionality and unbalanced lipid import/export, lead ... -
Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation
Barbier Torres, Lucía; Fortner, Karen A.; Iruzubieta, Paula; Delgado, Teresa C.; Giddings, Emily; Chen, Youdinghuan; Champagne, Devin; Fernández Ramos, David; Mestre, Daniela; Gómez Santos, Beatriz; Varela Rey, Marta; Gutiérrez de Juan, Virginia; Fernández Tussy, Pablo; Zubiete Franco, Imanol; García Monzón, Carmelo; González Rodríguez, Águeda; Oza, Dhaval; Valença Pereira, Felipe; Fang, Qian; Crespo, Javier; ; Tremblay, Frederic; Christensen, Brock C.; Anguita Castillo, Juan de Dios; Martínez Chantar, María Luz; Rincón, Mercedes (Nature, 2020-07-03)
Nonalcoholic fatty liver disease (NAFLD) is considered the next major health epidemic with an estimated 25% worldwide prevalence. No drugs have yet been approved and NAFLD remains a major unmet need. Here, we identify MCJ ...